

14 October 2025

ASX Announcement

Appointment of Non-Executive Director – Mr. Robert Douglas

PolyNovo Limited (**PolyNovo or the Company**) is pleased to announce that the Board has resolved to appoint Mr. Robert Douglas to the Board of Directors.

Mr. Douglas is an Australian and U.S. dual citizen, living in San Diego, but has a residence and family in Sydney.

Mr. Douglas has more than thirty-five years of experience in medical device technology, specialising in digital health. He also has a decade of experience in public company governance, including audit, risk management, and compliance oversight.

Mr. Douglas had a number of strategy and operational roles before joining ResMed Inc. Australia (NYSE: RMD, ASX: RMD) in 2001. Since then, he has had various roles in the U.S. and Australia including Vice President Corporate Marketing, Vice President Operations and President and Chief Operating Officer from 2013 to 2023. ResMed is a global medical device and software applications company providing solutions to diagnose, treat and manage respiratory disorders and improve care in out-of-hospital settings.

Mr. Douglas is currently a member of the Board of Directors and Audit Committee for Globus Medical Inc. (NYSE: GMED), a global musculoskeletal medical technology company.

Mr. Douglas holds a Master of Business Administration from Macquarie University, a Bachelor of Electrical Engineering with First Class Honors, and a Bachelor of Science in Computer Sciences from the University of New South Wales, Australia. He is also a Director Certified Member of the National Association of Corporate Directors in the U.S.

Chairman, David Williams said: *“Rob brings a blend of Australian and U.S. MedTech experience and culture to the Board. He also brings experience in expanding a business internationally. I also expect that his experience with patient data and the cloud at ResMed will enable us to look more widely at opportunities for PolyNovo.”*

This announcement has been authorised by the PolyNovo Board of Directors.

About PolyNovo®

PolyNovo is a disruptive medical technology company, based in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 84,000+ patients across 46 countries, the company is investing for growth with new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

About NovoSorb MTX®

NovoSorb MTX leverages the technology platform underpinning the clinical success of NovoSorb BTM, but **without a sealing membrane**, and is designed to support natural wound healing, especially for wounds that are highly exudative or those with an uneven wound bed. The product was developed to satisfy clinician demand for a product for use in indications where the sealing membrane is not required.

About Beta Cell

PolyNovo is supplying NovoSorb BTM to Beta Cell Technologies Pty Ltd for clinical trial purposes following positive results of the First in Man proof of concept study. The study involved transplanting human pancreatic islets into an alternative neovascularised site within the skin for 3 trial participants using NovoSorb BTM to create a cell supporting vascular bed.